Related references
Note: Only part of the references are listed.Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases
Leela Rani Avula et al.
MOLECULAR CANCER RESEARCH (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory
Wenhao Luo et al.
CANCER CELL INTERNATIONAL (2020)
Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
Asfar S. Azmi et al.
CLINICAL CANCER RESEARCH (2020)
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Heng Zhu et al.
MOLECULAR CANCER (2020)
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer
Austin R. Dosch et al.
MOLECULAR CANCER RESEARCH (2020)
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Sara K. Daniel et al.
SEMINARS IN CANCER BIOLOGY (2020)
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Yolla Haibe et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer
Li Ding et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer
Mohammad Aslam Khan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.
Quincy S. Chu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An open-label, single-arm, phase I study to assess the safety, efficacy, and biomarker effects of OMT-110 in patients with refractory colorectal cancer.
Soobong Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
Cristina Gasparetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cobimetinib plus gemcitabine is an active combination in KRAS G12R-mutated in previously chemotherapy-treated and failed pancreatic patients.
Bach Ardalan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.
Afshin Dowlati et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis
Keywan Mortezaee
LIFE SCIENCES (2020)
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Frank T. Zenke et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Adoptive Cell Therapy-Harnessing Antigen-Specific T cells to Target Solid Tumours
Elzbieta Chrusciel et al.
CANCERS (2020)
A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma
J. Jo et al.
ANNALS OF ONCOLOGY (2020)
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors
Ryan J. Sullivan et al.
CLINICAL CANCER RESEARCH (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity
Pu Sun et al.
ACTA PHARMACOLOGICA SINICA (2020)
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1
Theresa A. Proia et al.
CLINICAL CANCER RESEARCH (2020)
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
Yang Song et al.
DISEASE MARKERS (2020)
DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications
Kah Keng Wong
CELLULAR ONCOLOGY (2020)
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
Jean-Pascal Machiels et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer
Vincent Picozzi et al.
ESMO OPEN (2020)
Purinergic Signaling in Pancreas-From Physiology to Therapeutic Strategies in Pancreatic Cancer
Ivana Novak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials
Sophie Marie Anne Effing et al.
ECLINICALMEDICINE (2020)
Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy
Shenthol Sasankan et al.
CASE REPORTS IN ONCOLOGY (2020)
Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment
Jonas R. M. Van Audenaerde et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)
Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer
Shreya Gupta et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018)
F. Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Angiogenesis in pancreatic cancer: current research status and clinical implications
Shuo Li et al.
ANGIOGENESIS (2019)
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.
Muhammad Shaalan Beg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A randomized phase II study of cabiralizumab (cabira) plus nivolumab (vivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).
Andrea Wang-Gillam et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
Targeting Alterations in the RAF-MEK Pathway
Rona Yaeger et al.
CANCER DISCOVERY (2019)
Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies
Tiziana Annese et al.
CANCERS (2019)
Turning the corner on therapeutic cancer vaccines
Robert E. Hollingsworth et al.
NPJ VACCINES (2019)
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2019)
Identification of biomarkers and their functions in dasatinib-resistant pancreatic cancer using bioinformatics analysis
Jingsun Wei et al.
ONCOLOGY LETTERS (2019)
Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
Natalia Anahi Juiz et al.
FRONTIERS IN ONCOLOGY (2019)
High expression of CDK1 and BUB1 predicts poor prognosis of pancreatic ductal adenocarcinoma
Junjie Piao et al.
GENE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Next-Generation Sequencing in Pancreatic Cancer
Gong-Qing Shen et al.
PANCREAS (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Population pharmacokinetics of siltuximab: impact of disease state
Mina Nikanjam et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
CD73: an emerging checkpoint for cancer immunotherapy
Siqi Chen et al.
IMMUNOTHERAPY (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescence to apoptosis
Dongqin Yang et al.
EBIOMEDICINE (2019)
Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer
Goran Hamid Mohammad et al.
CANCERS (2019)
The Role of the Cyclin Dependent Kinase Inhibitor p21cip1/waf1 in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics
Samar Al Bitar et al.
CANCERS (2019)
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Kyle C. Cuneo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)
Silvia Bozzarelli et al.
FUTURE ONCOLOGY (2019)
The glycosylation landscape of pancreatic cancer
Jennifer Munkley
ONCOLOGY LETTERS (2019)
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
Medhavi Gupta et al.
CANCERS (2019)
Advances in Receptor-Mediated, Tumor-Targeted Drug Delivery
Danielle E. Large et al.
ADVANCED THERAPEUTICS (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results
Dana B. Cardin et al.
INVESTIGATIONAL NEW DRUGS (2018)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan et al.
CANCER DISCOVERY (2018)
New somatostatin-drug conjugates for effective targeting pancreatic cancer
E. Ragozin et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Genetic unrelatedness of co-occurring pancreatic adenocarcinomas and IPMNs challenges current views of clinical management
Aldo Scarpa et al.
GUT (2018)
Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
Jinyang Li et al.
IMMUNITY (2018)
Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer
Yoshinaga Okugawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Ruxolitinib plus capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
Herbert Hurwitz et al.
INVESTIGATIONAL NEW DRUGS (2018)
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab- Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
Sunil R. Hingorani et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.
Murray Yule et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial
Allen Cohn et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
Ramesh Butti et al.
MOLECULAR CANCER (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer
Yan Zhang et al.
ONCOLOGY LETTERS (2018)
Pancreatic Ductal Adenocarcinoma: A Strong imbalance of Good and Bad immunological Cops in the Tumor Microenvironment
Etienne D. Foucher et al.
FRONTIERS IN IMMUNOLOGY (2018)
Does Axl have potential as a therapeutic target in pancreatic cancer?
Wenting Du et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies.
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
Hongmei Jiang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
E E W Cohen et al.
ANNALS OF ONCOLOGY (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Christine Chen et al.
BLOOD (2018)
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
Kyaw Lwin Aung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.
Padmanee Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer
Kathleen F. Ludwig et al.
CANCER RESEARCH (2018)
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T. R. J. Evans et al.
ANNALS OF ONCOLOGY (2017)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Aleksandra Adamska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
Jaseela Chiramel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.
Davide Melisi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
Vincent J. Picozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Ohlund et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
CAR T-cell therapy for pancreatic cancer
Carl J. DeSelm et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
IL-17B: A new area of study in the IL-17 family
Qingli Bie et al.
MOLECULAR IMMUNOLOGY (2017)
Non-homologous DNA end joining and alternative pathways to double-strand break repair
Howard H. Y. Chang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
Lee S. Rosen et al.
TARGETED ONCOLOGY (2017)
Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review
Cheng-Ming Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Specific detection of soluble EphA2 fragments in blood as a new biomarker for pancreatic cancer
Naohiko Koshikawa et al.
CELL DEATH & DISEASE (2017)
TGF-β in pancreatic cancer initiation and progression: two sides of the same coin
Wei Shen et al.
CELL AND BIOSCIENCE (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
Hee Seung Lee et al.
SCIENTIFIC REPORTS (2017)
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway
Dawoon E. Jung et al.
SCIENTIFIC REPORTS (2017)
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
Joleen M. Hubbard et al.
DRUGS (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling
Bo Kong et al.
GUT (2016)
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
M. Buchert et al.
ONCOGENE (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
David B. Zhen et al.
INVESTIGATIONAL NEW DRUGS (2016)
A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Tremelimumab: research and clinical development
Begona Comin-Anduix et al.
ONCOTARGETS AND THERAPY (2016)
Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity
Charles H. Adelmann et al.
ONCOTARGET (2016)
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue
Vito Longo et al.
ONCOTARGET (2016)
Targeting DNA Replication Stress for Cancer Therapy
Jun Zhang et al.
GENES (2016)
Next frontiers in CAR T-cell therapy
Christine E. Brown et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
A. H. Ko et al.
CLINICAL CANCER RESEARCH (2015)
Cobimetinib: First Global Approval
Karly P. Garnock-Jones
DRUGS (2015)
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Albrecht Neesse et al.
GUT (2015)
Oncotropic H-1 parvovirus infection degrades HIF-1α protein in human pancreatic cancer cells independently of VHL and RACK1
Il-Rae Cho et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma
N. Cook et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer
Satoshi Nishiwada et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study
Alexandria T. Phan et al.
LANCET ONCOLOGY (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
Yujie Zhao et al.
ONCOLOGIST (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Profile of nintedanib in the treatment of solid tumors: the evidence to date
Niranjan Awasthi et al.
ONCOTARGETS AND THERAPY (2015)
HIF-1α pathway: role, regulation and intervention for cancer therapy
Georgina N. Masoud et al.
ACTA PHARMACEUTICA SINICA B (2015)
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt et al.
NATURE REVIEWS CANCER (2015)
Oncogenic KRAS signalling in pancreatic cancer
S. Eser et al.
BRITISH JOURNAL OF CANCER (2014)
The MAPK Pathway Across Different Malignancies: A New Perspective
Mauricio Burotto et al.
CANCER (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Sven Golfier et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Precursor Lesions for Sporadic Pancreatic Cancer: PanIN, IPMN, and MCN
M. Distler et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
Kai Hung Tiong et al.
APOPTOSIS (2013)
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
H. K. Ahn et al.
BRITISH JOURNAL OF CANCER (2013)
CD40 immunotherapy for pancreatic cancer
Robert H. Vonderheide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Trametinib: First Global Approval
Cameron J. M. Wright et al.
DRUGS (2013)
Dabrafenib: First Global Approval
Anita D. Ballantyne et al.
DRUGS (2013)
Cetuximab: still an option in the treatment of pancreatic cancer?
Luca Faloppi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
David S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2013)
Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma
Simon M. Denley et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Cheng Ean Chee et al.
ONCOLOGIST (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
Gyoergy Bodoky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab: Potential for Immune Modulation
Eric Luedke et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Checkpoint control and cancer
R. H. Medema et al.
ONCOGENE (2012)
Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors
Marcus W. Wiedmann et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity
Ritsuko Sawada et al.
CLINICAL CANCER RESEARCH (2011)
Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth
Nagathihalli S. Nagaraj et al.
CLINICAL CANCER RESEARCH (2011)
A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer
A. R. He et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Jens Rueter et al.
CANCER BIOLOGY & THERAPY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
TGFβ signalling: a complex web in cancer progression
Hiroaki Ikushima et al.
NATURE REVIEWS CANCER (2010)
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
F. Kullmann et al.
BRITISH JOURNAL OF CANCER (2009)
Clinical importance of B7-H3 expression in human pancreatic cancer
I. Yamato et al.
BRITISH JOURNAL OF CANCER (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis
Lihua Zeng et al.
CANCER SCIENCE (2008)
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
[Anonymous]
LANCET ONCOLOGY (2008)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial
HQ Xiong et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
CD8(+) tumor-infiltrating lymphocytes together with CD4(+) tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma
A Fukunaga et al.
PANCREAS (2004)
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
EM Jaffee et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
